Drug Development

Articles

Formulating an injectable solution containing both hydrophilic and hydrophobic drugs is a challenge.

In-Vivo Release Studies of Levamisole Phosphate and Ivermectin from an Isotropic Medium-Chain Mono and Diglyceride-Based Formulation Following Subcutaneous Injection in Sheep

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Working with biological matrices and understanding the intended use are crucial.

Developing and Validating Assays for Small-Molecule Biomarkers

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

New guidelines focused on the materials of construction in biologic therapy packaging will help vendors prepare comprehensive extractable and leachable testing strategies.

Special Considerations for Extractables and Leachables Testing in Biological Products

Agnes Shanley is senior editor of Pharmaceutical Technology.

CMO executives share their opinions on where outsourcing is going and what is driving market change.

The Future of Contract Services

After launching a new mammalian cell platform, FUJIFILM Diosynth Biotechnologies U.S.A., has acquired fast-track vaccine manufacturing knowhow and a major presence in Texas’ emerging biocorridor with Kalon, its first acquisition.

FUJIFILM's New Biopharm Game Plan

Catalent will add potent containment for blending and granulation at its New Jersey manufacturing Center of Excellence.

Catalent Expands High-Potency Handling Capability

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Government and industry efforts to address manufacturing challenges move Ebola vaccine candidates into larger clinical trials.

Ebola Treatments Ramp Up for Clinical Trials

A draft NIOSH Current Intelligence Bulletin on recommendations for reducing worker exposure to reproductive risks of drugs is available for public comment.

CDC Publishes Information on Reducing Worker Exposure to Hazardous Drugs

Catalent announced that it would partner with Mitsubishi Gas Chemical Company, and its subsidiary MGC Pharma, to promote GPEx technology, a high-titer vector for stable mammalian cell lines.

Catalent and MGC Pharma Partner for Production of Cell Lines

Sanofi has entered into a strategic manufacturing collaboration with Boehringer Ingelheim for the manufacture of therapeutic monoclonal antibodies (mAbs).

Formulation and Drug Delivery